Xuanzhu Biopharmaceutical Secures Third Indication Approval for Bireociclib Tablets — Major Expansion in Advanced Breast Cancer Market

Key Highlights

• Bireociclib Tablets (Xuanyuening) granted third marketing approval in China for first-line treatment of HR+/HER2- advanced breast cancer, in combination with aromatase inhibitors (AIs).
• This approval positions Bireociclib as the first and only drug in China to cover first-line, second-line, and later-line treatments for HR+/HER2- advanced breast cancer.
• The approval is based on the robust clinical results from the pivotal Phase III BRIGHT-3 study.
• The breast cancer market is large and growing rapidly, with significant market opportunity for CDK4/6 inhibitors in China.

Detailed Analysis for Investors

Xuanzhu Biopharmaceutical Co., Ltd. (“Xuanzhu” or “the Company”) announced a significant development that could potentially be a major catalyst for its share price. The National Medical Products Administration of China (NMPA) has granted marketing approval for Bireociclib Tablets (brand name: Xuanyuening), expanding its indications to include first-line treatment for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer in combination with aromatase inhibitors.

This milestone marks the third approved indication for Bireociclib in China, following its previous approvals for use in combination with fulvestrant and as a monotherapy. Importantly, Bireociclib is now the first and only drug in China that covers the full spectrum of first-line, second-line, and later-line treatments for HR+/HER2- advanced breast cancer. This broad coverage is likely to substantially enhance the drug’s clinical value, accessibility, and market penetration, supporting future sales growth.

Market Opportunity and Growth Potential

• Breast cancer remains the most diagnosed malignant tumor among women globally, with rapid growth in China.
• According to China Insights Consultancy, new breast cancer cases in China rose from 322,200 in 2018 to an estimated 374,700 in 2024, and are projected to reach 435,000 by 2032.
• HR+/HER2- is the most common subtype in China, accounting for approximately 75% of all breast cancer cases.
• About 30% of HR+/HER2- breast cancer patients are diagnosed at the advanced stage, emphasizing the need for effective treatment options.
• CDK4/6 inhibitors combined with endocrine therapy have become the standard first-line therapy for this patient population in China, and the market size for these inhibitors is expected to reach RMB 13 billion by 2032.

Clinical Data and Competitive Advantage

The NMPA’s decision was supported by the results of the pivotal Phase III BRIGHT-3 study (NCT05257395), a randomized, double-blind trial conducted at 58 centers across China. Key findings include:

• Progression-Free Survival (PFS): Median PFS was not reached in the Bireociclib group, indicating strong and durable efficacy, compared to 18.43 and 19.55 months in the control group.
• Risk Reduction: The Bireociclib regimen reduced the risk of disease progression or death by 47% compared to endocrine therapy plus placebo.
• Refractory Population: For patients with liver metastases (a group with poor prognosis), the risk of progression or death was reduced by 64%.
• Objective Response Rate (ORR): 63.5% in the Bireociclib group versus 42.5% in the control group.
• Safety: Common side effects, such as diarrhea and neutropenia, were mostly mild (Grade 1–2) and manageable.

Bireociclib’s unique mechanism as a CDK2/4/6 inhibitor offers potent anti-tumor activity with a significant reduction in hematological toxicity compared to traditional CDK4/6 inhibitors.

Recent Regulatory and Reimbursement Developments

• Bireociclib was first approved in May 2025 for use with Fulvestrant in HR+/HER2- advanced or metastatic breast cancer patients who have progressed after prior endocrine therapy, and as a monotherapy after two or more lines of endocrine therapies plus one chemotherapy in the metastatic setting.
• Bireociclib is the first and only CDK2/4/6 inhibitor in China approved for a monotherapy indication.
• As of December 2025, both approved indications have been included in China’s National Reimbursement Drug List (effective January 1, 2026), significantly improving patient access and the drug’s commercial prospects.
• PharmCube statistics note that Bireociclib has ranked first in the global CDK2/4/6 inhibitor market.

Shareholder and Price-Sensitive Considerations

• This announcement is a significant positive for Xuanzhu, as it expands the potential market for Bireociclib, a key growth driver for the company.
• The approval for first-line use in China’s largest breast cancer patient segment could materially boost future sales, revenue, and market share.
• Inclusion in the National Reimbursement Drug List further enhances accessibility and is likely to accelerate uptake.
• Investors should monitor upcoming sales data, post-launch adoption rates, and any new clinical data or regulatory filings in other indications or markets.

Conclusion: The new first-line indication for Bireociclib represents a major milestone for Xuanzhu Biopharmaceutical. The expanded label, coupled with favorable reimbursement status and strong clinical data, offers significant upside potential for the company’s future performance and could be highly price-sensitive for shareholders and the broader market.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Investors should consider their own circumstances and consult professional advisors before making any investment decisions. The author and publisher make no representations as to the completeness or accuracy of the information contained herein, and accept no liability for any losses arising from reliance on this content.

View XUANZHUBIO-B Historical chart here